## Mariano Malaguarnera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4557981/publications.pdf

Version: 2024-02-01

186 papers 7,699 citations

41344 49 h-index 79 g-index

187 all docs

187 docs citations

times ranked

187

10132 citing authors

#	Article	IF	CITATIONS
1	Anti-inflammatory role of vitamin D in muscle dysfunctions of patients with chronic obstructive pulmonary disease: a comprehensive review. Minerva Medica, 2023, 114, .	0.9	6
2	Vitamin D Impacts on Skeletal Muscle Dysfunction in Patients with COPD Promoting Mitochondrial Health. Biomedicines, 2022, 10, 898.	3.2	10
3	Impact of Lung Microbiota on COPD. Biomedicines, 2022, 10, 1337.	3.2	10
4	Protective role of vitamin D against oxidative stress in diabetic retinopathy. Diabetes/Metabolism Research and Reviews, 2021, 37, e3447.	4.0	23
5	Is the Power Spectrum of Electromyography Signal a Feasible Tool to Estimate Muscle Fiber Composition in Patients with COPD?. Journal of Clinical Medicine, 2021, 10, 3815.	2.4	13
6	Impact of chronic obstructive pulmonary disease on passive viscoelastic components of the musculoarticular system. Scientific Reports, 2021, 11, 18077.	3.3	8
7	Vitamin D and microbiota: Two sides of the same coin in the immunomodulatory aspects. International Immunopharmacology, 2020, 79, 106112.	3.8	60
8	Vitamin D3 as Potential Treatment Adjuncts for COVID-19. Nutrients, 2020, 12, 3512.	4.1	39
9	Influence of Resveratrol on the Immune Response. Nutrients, 2019, 11, 946.	4.1	319
10	Polyphenols: Plant Sources and Food Industry Applications. Current Pharmaceutical Design, 2019, 24, 4125-4130.	1.9	29
11	Fasting and Fast Food Diet Play an Opposite Role in Mice Brain Aging. Molecular Neurobiology, 2018, 55, 6881-6893.	4.0	23
12	Chitinases as Biomarkers in Bone Studies. Biomarkers in Disease, 2017, , 301-327.	0.1	1
13	Co-Expression and Co-Localization of Cartilage Glycoproteins CHI3L1 and Lubricin in Osteoarthritic Cartilage: Morphological, Immunohistochemical and Gene Expression Profiles. International Journal of Molecular Sciences, 2016, 17, 359.	4.1	65
14	Impact of gut microbiota on diabetes mellitus. Diabetes and Metabolism, 2016, 42, 303-315.	2.9	169
15	Chitotriosidase: A New Inflammatory Marker in Diabetic Complications. Pathobiology, 2016, 83, 211-219.	3.8	27
16	Chitinases and immunity: Ancestral molecules with new functions. Immunobiology, 2016, 221, 399-411.	1.9	100
17	CHI3L1 nuclear localization in monocyte derived dendritic cells. Immunobiology, 2016, 221, 347-356.	1.9	31
18	Autophagy in Diabetic Retinopathy. Current Neuropharmacology, 2016, 14, 810-825.	2.9	104

#	Article	IF	Citations
19	Hepatocellular carcinoma and the risk of occupational exposure. World Journal of Hepatology, 2016, 8, 573.	2.0	67
20	Chronic hepatitis C: This and the new era of treatment. World Journal of Hepatology, 2016, 8, 92.	2.0	69
21	New insights on chitinases immunologic activities. World Journal of Immunology, 2016, 6, 96.	0.5	4
22	Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. Frontiers in Pharmacology, 2015, 6, 226.	<b>3.</b> 5	15
23	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12.	1.9	25
24	Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation. Inflammation, 2015, 38, 2082-2091.	3.8	21
25	Association of trace elements with lipid profiles and glycaemic control in patients with type 1 diabetes mellitus in northern Sardinia, Italy: An observational study. Chemosphere, 2015, 132, 101-107.	8.2	26
26	Different pediatric brain tumors are associated with different gene expression profiling. Acta Histochemica, 2015, 117, 477-485.	1.8	31
27	Chitinases as Biomarkers in Bone Studies. Exposure and Health, 2015, , 1-27.	4.9	0
28	Renal Function and Ultrasound Imaging in Elderly Subjects. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	5
29	Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies. BioMed Research International, 2014, 2014, 1-15.	1.9	66
30	Rare Benign Tumors of the Liver: Still Rare?. Journal of Gastrointestinal Cancer, 2014, 45, 202-217.	1.3	13
31	Determination of chitinases family during osteoclastogenesis. Bone, 2014, 61, 55-63.	2.9	48
32	Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin: Effect on Work Performance. A Randomized Clinical Trial. Hepatitis Monthly, 2014, 14, e11608.	0.2	22
33	Post laryngectomy speech rehabilitation outcome in elderly patients. European Archives of Oto-Rhino-Laryngology, 2013, 270, 1879-1884.	1.6	16
34	Modulation of Chitotriosidase During Macrophage Differentiation. Cell Biochemistry and Biophysics, 2013, 66, 239-247.	1.8	48
35	Evaluation of CHI3L-1 and CHIT-1 Expression in Differentiated and Polarized Macrophages. Inflammation, 2013, 36, 482-492.	3.8	81
36	Association of chitotriosidase genotype with the development of nonâ€alcoholic fatty liver disease. Hepatology Research, 2013, 43, 267-275.	3.4	21

#	Article	IF	CITATIONS
37	Evaluation of AMCase and CHIT-1 expression in monocyte macrophages lineage. Molecular and Cellular Biochemistry, 2013, 374, 73-80.	3.1	33
38	Vitamin D3 insufficiency and colorectal cancer. Critical Reviews in Oncology/Hematology, 2013, 88, 594-612.	4.4	29
39	Metal fume fever. Lancet, The, 2013, 381, 2298.	13.7	7
40	Systemic therapies in hepatocellular carcinoma: present and future. Future Oncology, 2013, 9, 1533-1548.	2.4	42
41	Lipoprotein(a) in Cardiovascular Diseases. BioMed Research International, 2013, 2013, 1-9.	1.9	59
42	Neurotoxicity of Acrylamide in Exposed Workers. International Journal of Environmental Research and Public Health, 2013, 10, 3843-3854.	2.6	160
43	Comparison of YKL-39 and CHIT-1 expression during macrophages differentiation and polarization. Modern Research in Inflammation, 2013, 02, 82-89.	0.4	5
44	Autoimmunity in the elderly: Implications for cancer. Journal of Cancer Research and Therapeutics, 2012, 8, 520.	0.9	24
45	Long-Term Persistence of Seroprotection by Hepatitis B Vaccination in Healthcare Workers of Southern Italy. Hepatitis Monthly, 2012, 12, e6025.	0.2	13
46	Carnitine derivatives. Current Opinion in Gastroenterology, 2012, 28, 166-176.	2.3	86
47	Toxic hepatitis in occupational exposure to solvents. World Journal of Gastroenterology, 2012, 18, 2756.	3.3	120
48	Rasburicase for the treatment of tumor lysis in hematological malignancies. Expert Review of Hematology, 2012, 5, 27-38.	2.2	12
49	A musician's dystonia. Lancet, The, 2012, 379, 2116.	13.7	11
50	Prevalence of cardiovascular pathologies in elderly population living in an industrialized area, compared to a control population residing in a rural area. Archives of Gerontology and Geriatrics, 2012, 55, 702-705.	3.0	2
51	CYTOKINE SERUM PROFILE IN A GROUP OF SICILIAN NONAGENARIANS. Journal of Immunoassay and Immunochemistry, 2012, 33, 82-90.	1.1	35
52	Stabbing headache in patients with autoimmune disorders. Clinical Neurology and Neurosurgery, 2012, 114, 751-753.	1.4	18
53	The role of diet in gastric cancer: still an open question. Frontiers in Bioscience - Landmark, 2012, 17, 1640.	3.0	19
54	Probiotics in the gastrointestinal diseases of the elderly. Journal of Nutrition, Health and Aging, 2012, 16, 402-410.	3.3	65

#	Article	IF	CITATIONS
55	Genetic variants in candidate genes influencing NAFLD progression. Journal of Molecular Medicine, 2012, 90, 105-118.	3.9	39
56	Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scandinavian Journal of Gastroenterology, 2011, 46, 750-759.	1.5	69
57	The Supplementation of Acetyl- $<$ scp> $<$ l $<$ lscp>-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon- $\hat{l}_{\pm}$ 2b Plus Ribavirin. Journal of Interferon and Cytokine Research, 2011, 31, 653-659.	1.2	32
58	Vitamin D3: a helpful immuno-modulator. Immunology, 2011, 134, 123-139.	4.4	346
59	Non-melanoma skin cancers in elderly patients. Critical Reviews in Oncology/Hematology, 2011, 80, 474-480.	4.4	18
60	Oral acetyl-l-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. American Journal of Clinical Nutrition, 2011, 93, 799-808.	4.7	75
61	Authorâ∈™s Reply: Statin, Beyond Hyperlipidemia toward a Novel Agent for Hepatitis C. Hepatitis Monthly, 2011, 11, .	0.2	4
62	L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-l± 2b plus ribavirin. World Journal of Gastroenterology, 2011, 17, 4414.	3.3	42
63	Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with $\hat{\mathbf{l}}\pm$ -interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. Hepatitis Monthly, 2011, 11, 92-8.	0.2	21
64	Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2010, 22, 199-206.	1.6	101
65	Rhabdomyolysis Induced by Rosuvastatin and Sildenafil. Southern Medical Journal, 2010, 103, 1052-1054.	0.7	12
66	Serum Markers of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2010, 55, 2744-2755.	2.3	166
67	The value of glycosylated hemoglobin (HbA1c) as a predictive risk factor in the diagnosis of diabetes mellitus (DM) in the elderly. Archives of Gerontology and Geriatrics, 2010, 50, 60-64.	3.0	16
68	A combination of glycosylated hemoglobin, impaired fasting glucose and waist circumference is effective in screening for individuals at risk for future type 2 diabetes. Archives of Gerontology and Geriatrics, 2010, 50, 105-109.	3.0	9
69	Autopsy reports in extreme longevity. Archives of Gerontology and Geriatrics, 2010, 50, 48-50.	3.0	16
70	Red or white wine assumption and serum antioxidant capacity. Archives of Gerontology and Geriatrics, 2010, 51, e72-e74.	3.0	14
71	The role of immunity in elderly cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 40-60.	4.4	86
72	Human chitotriosidase polymorphism is associated with human longevity in Mediterranean nonagenarians and centenarians. Journal of Human Genetics, 2010, 55, 8-12.	2.3	22

#	Article	IF	Citations
73	L-Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis—A Randomized and Controlled Clinical Trial. American Journal of Gastroenterology, 2010, 105, 1338-1345.	0.4	191
74	A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opinion on Pharmacotherapy, 2009, 10, 737-742.	1.8	36
75	Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2009, 10, 1875-1882.	1.8	43
76	l-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. American Journal of Clinical Nutrition, 2009, 89, 71-76.	4.7	99
77	Prolactin induces chitotriosidase expression in human macrophages through PTK, PI3â€K, and MAPK pathways. Journal of Cellular Biochemistry, 2009, 107, 881-889.	2.6	33
78	Egg white injury. Internal and Emergency Medicine, 2009, 4, 79-81.	2.0	6
79	Molecular mechanisms involved in NAFLD progression. Journal of Molecular Medicine, 2009, 87, 679-695.	3.9	250
80	The significance of apolipoprotein-B (Apo-B) in the elderly as a predictive factor of cardio-cerebrovascular complications. Archives of Gerontology and Geriatrics, 2009, 49, 162-164.	3.0	5
81	The metabolic syndrome (MS) in the elderly: Considerations on the diagnostic criteria of the International Diabetes Federation (IDF) and some proposed modifications. Archives of Gerontology and Geriatrics, 2009, 48, 380-384.	3.0	23
82	The health-care in the extreme longevity. Archives of Gerontology and Geriatrics, 2009, 49, 32-34.	3.0	29
83	Bilateral benign blepharoclonus. Clinical Neurology and Neurosurgery, 2009, 111, 480-481.	1.4	1
84	Effect of l-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism: Clinical and Experimental, 2009, 58, 1618-1623.	3.4	34
85	Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. European Journal of Gastroenterology and Hepatology, 2009, 21, 762-770.	1.6	27
86	Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome. Digestive Diseases and Sciences, 2008, 53, 830-835.	2.3	171
87	Acetyl-l-Carnitine Treatment in Minimal Hepatic Encephalopathy. Digestive Diseases and Sciences, 2008, 53, 3018-3025.	2.3	86
88	The role of exercise on the innate immunity of the elderly. European Review of Aging and Physical Activity, 2008, 5, 43-49.	2.9	15
89	Acquired immunity: immunosenescence and physical activity. European Review of Aging and Physical Activity, 2008, 5, 61-68.	2.9	8
90	Insulin-resistance (IR) in older age. Archives of Gerontology and Geriatrics, 2008, 46, 203-209.	3.0	8

#	Article	IF	Citations
91	Cognitive and functional status in the extreme longevity. Archives of Gerontology and Geriatrics, 2008, 46, 245-252.	3.0	24
92	A review on the actual trends of insulin treatment in elderly with diabetes. Archives of Gerontology and Geriatrics, 2008, 47, 151-161.	3.0	5
93	Efficacy and limits of sildenafil citrate in patients with arterial erectile dysfunction: role of peripheral arterial disease and cardiovascular comorbidities. Asian Journal of Andrology, 2008, 10, 847-853.	1.6	4
94	Laboratory parameters in centenarians of Italian ancestry. Experimental Gerontology, 2008, 43, 119-122.	2.8	28
95	The extreme longevity: The state of the art in Italy. Experimental Gerontology, 2008, 43, 45-52.	2.8	64
96	Diabetes mellitus in the extreme longevity. Experimental Gerontology, 2008, 43, 102-105.	2.8	27
97	l-Carnitine Treatment Reduces Steatosis in Patients with Chronic Hepatitis C Treated with $\hat{l}_{\pm}$ -Interferon and Ribavirin. Digestive Diseases and Sciences, 2008, 53, 1114-1121.	2.3	34
98	Sexual Dysfunction in Chronic Hepatitis C Virus Patients Treated with Interferon Alpha and Ribavirin. Journal of Interferon and Cytokine Research, 2008, 28, 603-610.	1.2	15
99	l-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. American Journal of Clinical Nutrition, 2007, 86, 1738-1744.	4.7	100
100	Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. International Journal of Medical Sciences, 2007, 4, 83-93.	<b>2.</b> 5	100
101	Tumor lysis syndrome in elderly. Critical Reviews in Oncology/Hematology, 2007, 64, 31-42.	4.4	25
102	Cardio-cerebrovascular complications in elderly with diabetes. Archives of Gerontology and Geriatrics, 2007, 44, 261-269.	3.0	13
103	Value and significance of new diagnostic criteria of diabetes mellitus in older people. Archives of Gerontology and Geriatrics, 2007, 45, 103-108.	3.0	11
104	Genealogy of centenarians and their relatives: A study of 12 families. Archives of Gerontology and Geriatrics, 2007, 45, 97-102.	3.0	8
105	Bifidobacterium longum with Fructo-Oligosaccharide (FOS) Treatment in Minimal Hepatic Encephalopathy: A Randomized, Double-Blind, Placebo-Controlled Study. Digestive Diseases and Sciences, 2007, 52, 3259-3265.	2.3	162
106	l-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. American Journal of Clinical Nutrition, 2007, 86, 1738-1744.	4.7	47
107	Hepatitis C virus in elderly cancer patients. European Journal of Internal Medicine, 2006, 17, 325-329.	2,2	30
108	L-carnitine Reduces Severity of Physical and Mental Fatigue and Improves Daily Activities in the Elderly. Southern Medical Journal, 2006, 99, 315-316.	0.7	15

#	Article	IF	CITATIONS
109	New Possibilities of Treatment for Panic Attacks in Elderly Patients. Journal of Clinical Psychopharmacology, 2006, 26, 67-70.	1.4	27
110	Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. European Journal of Neuroscience, 2006, 23, 2648-2656.	2.6	93
111	Interleukinâ€18 and transforming growth factorâ€beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology, 2006, 26, 307-312.	1.2	83
112	Diabetes mellitus in the elderly: Diagnostic features. Archives of Gerontology and Geriatrics, 2006, 42, 101-106.	3.0	14
113	The chromogranin-A (CgA) in prostate cancer. Archives of Gerontology and Geriatrics, 2006, 43, 117-126.	3.0	29
114	Effects of l-Acetylcarnitine on Cirrhotic Patients with Hepatic Coma: Randomized Double-Blind, Placebo-Controlled Trial. Digestive Diseases and Sciences, 2006, 51, 2242-2247.	2.3	46
115	The management of tumor lysis syndrome. Nature Clinical Practice Oncology, 2006, 3, 438-447.	4.3	115
116	Potential Role of Chitotriosidase Gene in Nonalcoholic Fatty Liver Disease Evolution. American Journal of Gastroenterology, 2006, 101, 2060-2069.	0.4	70
117	Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World Journal of Gastroenterology, 2006, 12, 4541.	3.3	52
118	Somatomedin C (IGF-1), Dehydroepiandrosterone Sulphate (DHEA-S) and Hcy Metabolism in Postmenopausal African Women. Journal of Medical Sciences (Faisalabad, Pakistan), 2006, 6, 734-742.	0.0	1
119	Successful aging in centenarians: myths and reality. Archives of Gerontology and Geriatrics, 2005, 40, 241-251.	3.0	126
120	An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded― post-stroke depression. Archives of Gerontology and Geriatrics, 2005, 40, 275-285.	3.0	59
121	Effects of L-carnitine in patients with hepatic encephalopathy. World Journal of Gastroenterology, 2005, 11, 7197.	3.3	85
122	Effect of interferon-Î <sup>3</sup> , interleukin-10, lipopolysaccharide and tumor necrosis factor-α on chitotriosidase synthesis in human macrophages. Clinical Chemistry and Laboratory Medicine, 2005, 43, 499-502.	2.3	70
123	Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. Journal of Hepatology, 2005, 42, 585-591.	3.7	143
124	Serum carnitine levels in patients with tumoral cachexia. European Journal of Internal Medicine, 2005, 16, 419-423.	2.2	48
125	Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1032-5.	2.3	64
126	Evaluation of the Prophylactic Efficacy of Amitriptyline and Citalopram, Alone or in Combination, in Patients with Comorbidity of Depression, Migraine, and Tension-Type Headache. Neuropsychobiology, 2004, 50, 322-328.	1.9	42

#	Article	IF	Citations
127	Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status. Clinical Chemistry and Laboratory Medicine, 2004, 42, 164-70.	2.3	15
128	Elevated plasma total homocysteine in centenarians. Clinical Chemistry and Laboratory Medicine, 2004, 42, 307-10.	2.3	11
129	Efficacy of Human Recombinant Erythropoietin plus IFN- $\hat{l}$ ± in Patients Affected by Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2004, 24, 594-599.	1.2	3
130	Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology, 2004, 173, 73-78.	3.1	72
131	Interleukin-2 Plus Ribavirin Versus Interferon-??-2b Plus Ribavirin in Patients with Chronic Hepatitis C Who Did Not Respond to Previous Interferon-??-2b Treatment. BioDrugs, 2004, 18, 407-413.	4.6	4
132	Intravenous Immunoglobulin Plus Interferon-?? in Autoimmune Hepatitis C. BioDrugs, 2004, 18, 63-70.	4.6	7
133	Ultrasound evaluation of centenarians' gallbladder. European Journal of Internal Medicine, 2004, 15, 45-49.	2.2	1
134	Helicobacter pylori and Alzheimer's disease: a possible link. European Journal of Internal Medicine, 2004, 15, 381-386.	2.2	96
135	Efficacy of Human Recombinant Erythropoietin plus IFN- $\hat{l}$ ± in Patients Affected by Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2004, 24, 594-599.	1.2	2
136	B cells in the aged: CD27, CD5, and CD40 expression. Mechanisms of Ageing and Development, 2003, 124, 389-393.	4.6	123
137	Plasma chitotriosidase activity in patients with βâ€thalassemia. American Journal of Hematology, 2003, 72, 285-286.	4.1	16
138	Alterations of the lymphocytic set-up in elderly patients with cancer. Archives of Gerontology and Geriatrics, 2003, 36, 7-14.	3.0	11
139	Can ultrasonographic findings of perihepatic lymphadenopathy promote investigations to detect possible presence of virus C infection in non-symptomatic subjects?. Hepatology Research, 2003, 27, 124-128.	3.4	12
140	Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clinica Chimica Acta, 2003, 331, 79-85.	1.1	79
141	Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue. Drugs and Aging, 2003, 20, 761-767.	2.7	75
142	Plasma Lipid Composition and LDL Oxidation. Clinical Chemistry and Laboratory Medicine, 2003, 41, 56-60.	2.3	46
143	<i>L</i> -Carnitine in the Treatment of Mild or Moderate Hepatic Encephalopathy. Digestive Diseases, 2003, 21, 271-275.	1.9	44
144	<i>L</i> -Carnitine Decreases Severity and Type of Fatigue Induced by Interferon-α in the Treatment of Patients with Hepatitis C. Neuropsychobiology, 2003, 47, 94-97.	1.9	37

#	Article	IF	Citations
145	Malignant Melanoma of Nasal Cavity: Case Report and Review of the Literature. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 29-34.	1.0	2
146	Effects of Carnitine on Biochemical Responses in Patients with Chronic Hepatitis C Treated with Interferon-??. Clinical Drug Investigation, 2002, 22, 443-448.	2.2	15
147	Nutritional and racial determinants of the increase in plasma homocysteine levels after methionine loading. Current Therapeutic Research, 2002, 63, 459-473.	1.2	7
148	Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease. Parasite Immunology, 2002, 24, 387-389.	1.5	50
149	Plasma levels of interleukin-18 and interleukin-12 in Plasmodium falciparum malaria. Parasite Immunology, 2002, 24, 489-492.	1.5	32
150	The leptin, a new hormone of adipose tissue: clinical findings and perspectives in geriatrics. Archives of Gerontology and Geriatrics, 2002, 34, 47-54.	3.0	7
151	Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis. Archives of Gerontology and Geriatrics, 2002, 34, 117-122.	3.0	22
152	Prescribing behavior for the elderly in the United Arab Emirates: psychotropic medication use remains low despite rising overall appropriate and inappropriate medication use. Archives of Gerontology and Geriatrics, 2002, 35, 35-44.	3.0	8
153	Association between the MHC class I gene HFE polymorphisms and longevity: a study in Sicilian population. Genes and Immunity, 2002, 3, 20-24.	4.1	56
154	Oxidized LDL Antibodies (OLAB) in Patients with & Data amp; beta; Thalassemia Major. Journal of Atherosclerosis and Thrombosis, 2002, 9, 139-144.	2.0	25
155	Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells. International Journal of Molecular Medicine, 2002, 10, 433-40.	4.0	41
156	Plasma chitotriosidase activity in $\hat{l}^2$ -thalassemia major: a comparative study between Sicilian and Sardinian patients. Clinica Chimica Acta, 2001, 306, 91-96.	1.1	20
157	Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. European Journal of Clinical Pharmacology, 2001, 57, 267-273.	1.9	14
158	Correlation between the bone mass, psychometric performances, and the levels of autonomy and autosufficiency in an elderly Italian population above 80 years of age. Archives of Gerontology and Geriatrics, 2001, 33, 265-271.	3.0	5
159	Neuropsychiatric Effects and Type of IFN- $\hat{l}\pm$ in Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2001, 21, 273-278.	1.2	55
160	The care of elderly, terminally ill oncological patients in caregiving sanitary residences. Archives of Gerontology and Geriatrics, 2000, 31, 85-94.	3.0	1
161	Assessment of cognitive and affective disorders in an elderly population undergoing hemodialysis. Archives of Gerontology and Geriatrics, 2000, 29, 239-247.	3.0	8
162	Plasma homocysteine concentrations in a healthy population living in Burkina Faso. Current Therapeutic Research, 2000, 61, 659-668.	1.2	10

#	Article	IF	Citations
163	Efficacy of Interferon-Based Therapy in the Treatment of Thalassaemic Patients with Chronic Hepatitis C. BioDrugs, 2000, 14, 137-140.	4.6	O
164	Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias. British Journal of Clinical Pharmacology, 1999, 48, 605-609.	2.4	18
165	Serum Carnitine Levels in Chronic Hepatitis C Patients Before and After Lymphoblastoid Interferon-?? Treatment. BioDrugs, 1999, 12, 65-69.	4.6	10
166	Interferon-?? Therapy in Sicilian and Sardinian Polytransfused Thalassaemic Patients with Chronic Hepatitis C. BioDrugs, 1999, 12, 55-63.	4.6	6
167	Fish Oil Treatment of Interferon-Alpha-Induced Dyslipidaemia. BioDrugs, 1999, 11, 285-291.	4.6	5
168	Serum Carnitine Levels in Centenarians. Clinical Drug Investigation, 1999, 17, 321-327.	2.2	7
169	Correlations between C-reactive protein, interleukin-6, tumor necrosis factor-α and body mass index during senile osteoporosis. Archives of Gerontology and Geriatrics, 1998, 27, 159-163.	3.0	23
170	A comparison of four types of interferon alpha in the treatment of chronic hepatitis C. Current Therapeutic Research, 1998, 59, 48-59.	1.2	9
171	Efficacy of different schedules in the management of chronic hepatitis C with interferon-oc. Annals of Medicine, 1998, 30, 213-217.	3.8	9
172	Tacrine Treatment of Alzheimer's Disease: Many Expectations,Few Certainties. Neuropsychobiology, 1998, 38, 226-231.	1.9	5
173	Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. Journal of Gastroenterology, 1997, 32, 211-215.	5.1	108
174	Cavernous haemangioma of the liver and pregnancy. Lancet, The, 1996, 347, 772.	13.7	3
175	Liver haemangioma and pregnancy. Lancet, The, 1996, 347, 1693-1694.	13.7	3
176	The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis. Current Therapeutic Research, 1996, 57, 646-662.	1.2	4
177	Effect of Interferon on Blood Lipids. Clinical Drug Investigation, 1996, 11, 43-48.	2.2	6
178	Lipid Profile in Centenarians. Clinical Drug Investigation, 1996, 11, 240-244.	2,2	2
179	Impaired Thermal and Tactile Sensitivity during Interferon- $\hat{l}_{\pm}$ Treatment. Clinical Drug Investigation, 1996, 12, 271-273.	2.2	2
180	Erythropoietin in healthy elderly subjects. Archives of Gerontology and Geriatrics, 1996, 22, 131-135.	3.0	3

#	ARTICLE	IF	CITATIONS
181	Mapped Auditory Evoked Potentials Before and After Interferon Treatment. Journal of Interferon and Cytokine Research, 1996, 16, 441-446.	1.2	4
182	Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clinical Therapeutics, 1995, 17, 721-728.	2.5	23
183	Beta2-microglobulin levels before and after interferon treatment in patients with chronic hepatitis C. Current Therapeutic Research, 1995, 56, 269-279.	1.2	0
184	Treatment of inoperable ovarian cancer with interleukin-2 and carboplatinum. Lancet, The, 1995, 346, 1627.	13.7	0
185	Possible role of the transcription factor interferon regulatory factor 1 (IRF-1) in the regulation of ornithine decarboxylase (ODC) gene expression during IFNI <sup>3</sup> macrophage activation. FEBS Letters, 1994, 348, 177-180.	2.8	7
186	Accumulation of ornithine decarboxylase mRNA accompanies activation of human and mouse monocytes/macrophages. FEBS Letters, 1990, 268, 32-34.	2.8	22